Fig. 6: Using the PPI analysis model as a predictive biomarker for in vivo ABT-199 response.
a, Schematic of the study. Complete blood cell count analysis was carried out on a daily basis to count the number of AML blasts in the primary AML samples. b–d, Comparison of the PPI profiles from the BC-6524 and BC-7230 samples. Clinical features and the estimated scores with PPI diagnostic results for ABT-199 (b), comparison of BCL2-family PPI profiles (n = 10 independent images) (c), changes in in vivo AML blast counts through the days after ABT-199 administration (d). e, Confusion matrix for the drug response prediction based on the estimated score and the in vivo drug responses (n = 10). f, Comparison of the estimated scores of patients with AML between responsive (n = 4) and non-responsive (n = 6) patients for in vivo ABT-199 administration (two-sided Mann–Whitney test, *P = 0.014). For the boxplots, the centre line represents the median, the box limits are the upper and lower quartiles, and the whiskers represent 1.5× interquartile range. g, Clinical features and the ABT-199 administration history of BC-7107. h, Tracking the changes in BCL2-family PPI profiles after relapse of BC-7107-R (n = 10 independent images). i, Tracking the changes in BIMBH3 PBA profiles and PPI diagnostic results after relapse of BC-7107-R. The data were normalized to the BCL2-BIMBH3 PBA level of HL60 cells. j, Changes in in vivo AML blast counts from BC-7107-R through the days after ABT-199 administration. The estimated scores were calculated from the model in Fig. 4f (b,g). Data represent means ± s.d.
